Clinical Response to a PARP Inhibitor and Chemotherapy in a Child with BARD1-Mutated Refractory Neuroblastoma: A Case...

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• High-risk neuroblastoma remains a deadly pediatric cancer, with limited treatment options for refractory cases.
• Synthetic lethality strategies, targeting homologous recombination deficiency (HRD), show promise in adult cancers.
• Germline mutations in homologous recombination repair genes can cause HRD.

Approach:

• A pediatric patient with refractory neuroblastoma and a germline BARD1 mutation was treated.
• Treatment involved a combination of a PARP inhibitor (talazoparib), chemotherapy, and radiation.
• Tumor BARD1 loss was confirmed via allele-specific expression in RNA-seq.

Key Points:

• Successful treatment of refractory neuroblastoma in a pediatric patient with a BARD1 mutation using talazoparib.
• Tumor exhibited bi-allelic BARD1 loss, yet HRD score was below the adult classification threshold.
• Highlights the potential of PARP inhibition in BARD1-mutated pediatric neuroblastoma.

Conclusions:

• PARP inhibition combined with DNA-damaging agents is a viable strategy for BARD1-mutated neuroblastoma.
• The HRD score alone may not be a reliable biomarker for this pediatric population.
• Further research is warranted for targeted therapies in pediatric cancers with specific genetic mutations.